BRII-B (02137) has announced that on April 16, 2026, it submitted an arbitration claim against Vir Biotechnology, Inc. to Judicial Arbitration and Mediation Services, Inc. in the United States. The claim relates to a contractual dispute arising from a collaboration agreement and a letter agreement. BRII-B alleges that Vir breached the terms of these agreements and is seeking remedies including: (1) specific performance of relevant obligations under the agreements, requiring Vir to transfer the production of elebsiran to BRII-B or its contractors; and (2) compensation for all losses suffered by BRII-B due to the alleged breaches. These losses include, but are not limited to, lost profits resulting from the alleged breaches and funds already invested by BRII-B in the collaboration based on reliance on Vir's explicit promises and covenant of good faith. The company will continue to seek legal advice and take necessary actions to protect its best interests.